Pfizer Inc. (NYSE:PFE) Stock Holdings Boosted by Cable Hill Partners LLC

Cable Hill Partners LLC increased its position in Pfizer Inc. (NYSE:PFE) by 20.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 21,344 shares of the biopharmaceutical company’s stock after acquiring an additional 3,632 shares during the period. Cable Hill Partners LLC’s holdings in Pfizer were worth $566,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PFE. Whipplewood Advisors LLC bought a new position in Pfizer in the 4th quarter worth approximately $108,000. Corrado Advisors LLC grew its stake in shares of Pfizer by 15.2% in the fourth quarter. Corrado Advisors LLC now owns 70,974 shares of the biopharmaceutical company’s stock worth $1,883,000 after purchasing an additional 9,357 shares in the last quarter. National Pension Service increased its holdings in shares of Pfizer by 2.9% during the fourth quarter. National Pension Service now owns 11,855,947 shares of the biopharmaceutical company’s stock valued at $314,538,000 after purchasing an additional 339,178 shares during the period. DMKC Advisory Services LLC bought a new stake in shares of Pfizer during the fourth quarter valued at about $1,482,000. Finally, Advisor OS LLC grew its position in Pfizer by 8.4% in the 4th quarter. Advisor OS LLC now owns 53,542 shares of the biopharmaceutical company’s stock valued at $1,420,000 after buying an additional 4,140 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $26.40 on Thursday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a market cap of $149.63 billion, a PE ratio of 18.73, a PEG ratio of 0.64 and a beta of 0.64. The stock’s 50-day moving average price is $26.34 and its two-hundred day moving average price is $27.36.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the business earned $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. Pfizer’s payout ratio is currently 121.99%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Guggenheim reiterated a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.